RecruitingNCT05851677
Disitamab Vedotin (RC48-ADC) in Breast Cancer
Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real-world Study
Sponsor
RenJi Hospital
Enrollment
45 participants
Start Date
Jun 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Eligibility
Inclusion Criteria2
- Histologically confirmed breast cancer;
- Prior or current use of Disitamab vedotin (RC48-ADC);
Exclusion Criteria1
- Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Interventions
DRUGDisitamab vedotin
recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05851677
Related Trials
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
NCT0661828763 locations
Early Phase Study of KESONOTIDE™in Participants With Solid Tumours
NCT069260753 locations
Cardiac Outcomes With Near-Complete Estrogen Deprivation
NCT053096553 locations
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT041190243 locations
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
NCT074780161 location